Our Services
Medical Information
Helpful Resources
Published on: 10/1/2026
Shingrix, the recombinant shingles vaccine used in the U.S. today, contains no live virus, so it cannot spread shingles or chickenpox to anyone around you. The older live vaccine, Zostavax, carried a very small theoretical risk of transmission if a vaccine-related rash developed, but it was discontinued in the U.S. in November 2020. Common reactions like soreness, fatigue, headache, or a low fever typically fade within two to three days and are signs of immune response, not infection, though timing and exceptions matter, so see below for the full details. If a widespread rash, blisters, or symptoms lasting longer than a few days appear, that may point to something other than a normal vaccine reaction and deserves a closer look. Since post-vaccine soreness can look a lot like the earliest signs of actual shingles, running a free, instant symptom check takes only a couple of minutes and can help you tell routine side effects from a problem worth bringing to a clinician right away.
Last reviewed for medical accuracy: 10/01/2026
Are You Contagious After the Shingles Vaccine?
How long after shingles vaccine are you contagious?
Shingles (herpes zoster) is caused by reactivation of the chickenpox virus (varicella-zoster virus) in nerves. Vaccination dramatically lowers your risk of developing shingles and its complications. Two vaccines are currently used in the U.S.:
Because they work differently, the chance of passing anything on to someone else differs. Below, you’ll find clear, evidence-based information about how long you might be contagious—if at all—after your shingles shot.
Shingrix is a non-live vaccine. It contains a protein from the virus plus an ingredient that boosts immune response (adjuvant). Because it does not contain any live virus, you cannot:
Key point
How long after shingles vaccine are you contagious? With Shingrix, you’re never contagious—you cannot infect anyone because there’s no live virus in the shot.
Zostavax uses a weakened form of the varicella-zoster virus. Live vaccines can occasionally replicate enough to trigger mild symptoms. In very rare cases, a rash can develop at the injection site, and live virus in the blisters could be transmitted to someone who has never had chickenpox or chickenpox vaccine.
Both vaccines can cause side effects. Typical reactions are immune responses, not signs of active infection:
These symptoms are not contagious. They reflect your immune system gearing up to protect you against shingles.
In practice, the chance that you could pass on varicella-zoster virus after a shingles shot is extremely low.
If you worry about infecting someone especially vulnerable (newborns, pregnant people, immunocompromised), you can take simple steps:
After vaccination, track how you feel. Most reactions are mild and resolve within a few days. If you experience:
…you should seek medical care immediately. These could signal serious side effects or unrelated conditions needing prompt attention.
For peace of mind, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It’s fast, confidential, and can help you decide if you need to talk with a doctor right away.
Most people will never experience any shedding or transmission risk. Vaccination remains the best way to prevent painful shingles outbreaks and long-term nerve pain (postherpetic neuralgia).
Always reach out if you have:
Your healthcare provider knows your medical history best. Call them for personalized advice, especially if anything feels life-threatening or persists beyond a few days.
Stay informed, stay healthy, and enjoy the strong protection that shingles vaccines offer—without worrying about infecting others.
(References)
* Chilek K, Routhouska S, Tamburro J. Disseminated varicella zoster virus in an immunized child as the acquired immunodeficiency syndrome-defining illness. Pediatr Dermatol. 2010 Mar-Apr;27(2):192-4. doi: 10.1111/j.1525-1470.2009.00942.x. Epub 2009 Jul 20. PMID: 19686302.
* Awasthi S, Lubinski JM, Shaw CE, Barrett SM, Cai M, Wang F, Betts M, Kingsley S, Distefano DJ, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. J Virol. 2011 Oct;85(20):10472-86. doi: 10.1128/JVI.00849-11. Epub 2011 Aug 3. PMID: 21813597; PMCID: PMC3187515.
* van Hoek AJ, Melegaro A, Gay N, Bilcke J, Edmunds WJ. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine. 2012 Feb 1;30(6):1225-34. doi: 10.1016/j.vaccine.2011.11.026. Epub 2011 Nov 23. PMID: 22119592.
* Kim KH. Herpes zoster vaccination. Korean J Pain. 2013 Jul;26(3):242-8. doi: 10.3344/kjp.2013.26.3.242. Epub 2013 Jul 1. PMID: 23861997; PMCID: PMC3710937.
* Gabutti G, Franchi M, Maniscalco L, Stefanati A. Varicella-zoster virus: pathogenesis, incidence patterns and vaccination programs. Minerva Pediatr. 2016 Jun;68(3):213-25. PMID: 27125440.
* Matthews I, Lu X, Dawson H, Bricout H, O'Hanlon H, Yu E, Nozad B. Assessing the effectiveness of zoster vaccine live: A retrospective cohort study using primary care data in the United Kingdom. Vaccine. 2018 Nov 12;36(46):7105-7111. doi: 10.1016/j.vaccine.2018.08.037. Epub 2018 Sep 5. PMID: 30195489.
* Luan N, Cao H, Wang Y, Lin K, Liu C. Ionizable Lipid Nanoparticles Enhanced the Synergistic Adjuvant Effect of CpG ODNs and QS21 in a Varicella Zoster Virus Glycoprotein E Subunit Vaccine. Pharmaceutics. 2022 Apr 30;14(5). doi: 10.3390/pharmaceutics14050973. Epub 2022 Apr 30. PMID: 35631559; PMCID: PMC9143440.
* Bakker KM, Eisenberg MC, Woods RJ, Martinez ME. Identifying optimal vaccination scenarios to reduce varicella zoster virus transmission and reactivation. BMC Med. 2022 Oct 8;20(1):387. doi: 10.1186/s12916-022-02534-7. Epub 2022 Oct 8. PMID: 36209074; PMCID: PMC9548166.
* Xie J, Yan XT, Zhang Q, Xu Y, Zhang XH, Yao DM, Xu JH. [Analysis of herpes zoster vaccination intention and related factors among ≥50-year-old patients with multiple chronic diseases in Zhejiang Province]. Zhonghua Yu Fang Yi Xue Za Zhi. 2026 Feb 6;60(2):205-212. doi: 10.3760/cma.j.cn112150-20250212-00101. PMID: 41606975.
* Alolayan SA, Sulaiman AA, Almogbel FS, Alsaud JS, Alsaif MS, Alharbi AM, Alrebdi MI. Assessment of populations' knowledge and willingness to receive Herpes Zoster Vaccine: A cross-sectional study from Qassim Region, Saudi Arabia. J Family Med Prim Care. 2026 Feb;15(2):895-903. doi: 10.4103/jfmpc.jfmpc_615_25. Epub 2026 Mar 20. PMID: 42023333; PMCID: PMC13098875.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.